Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.83 |
| ▸ | AXL | P30530 | 10/20 | 0.83 |
| ▸ | KDR | P35968 | 7/20 | 0.83 |
| ▸ | MERTK | Q12866 | 6/20 | 0.76 |
| ▸ | RET | P07949 | 3/20 | 0.74 |
| ▸ | KIT | P10721 | 3/20 | 0.74 |
| ▸ | FLT3 | P36888 | 3/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.72 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.72 |
| ▸ | FLT1 | P17948 | 3/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.69 |
| ▸ | AURKA | O14965 | 2/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693522 | 1.00 | MET (0.83) | METAXLKDRMERTKRET | |
| SCHEMBL29693523 | 1.00 | MET (0.83) | METAXLKDRMERTKRET | |
| SCHEMBL17867476 | 0.97 | MET (0.77) | METAXLKDRMERTKRET | |
| SCHEMBL19372980 | 0.95 | MET (0.74) | METAXLKDRMERTKRET | |
| SCHEMBL17867475 | 0.94 | MET (0.73) | METAXLKDRMERTKRET | |
| SCHEMBL10449248 | 0.92 | AXL (0.76) | METAXLKDRMERTKRET | |
| SCHEMBL24240662 | 0.92 | AXL (0.72) | METAXLKDRMERTKRET | |
| SCHEMBL12443877 | 0.92 | MET (0.71) | METAXLKDRMERTKRET | |
| SCHEMBL18676722 | 0.91 | AXL (0.82) | METAXLKDRMERTKRET | |
| SCHEMBL18676721 | 0.91 | AXL (0.82) | METAXLKDRMERTKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | ANGEX PHARMACEUTICAL, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | MET 2/4885AXL 239/4885KDR 5/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885KDR 5/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885KDR 5/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885KDR 5/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885AXL 109/4885KDR 4/4885 |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | UCK2, ULK2, CDK9 | MET 1893/4885AXL 437/4885KDR 3201/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | MET 2/4885AXL 239/4885KDR 5/4885 |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | UCK2, ULK2, CDK9 | MET 1893/4885AXL 437/4885KDR 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.